GASTROINTESTINAL CANCERS
Gastrointestinal (GI) cancers are a group of cancers that affect the GI tract and accessory organs of the digestive system, such as colorectal cancer, gastric cancer, esophageal cancer, pancreatic cancer, liver cancer and gastrointestinal stromal tumor (GIST).
Different treatment strategies are available for GI cancers depending on the cancer type and disease stage – including surgery, chemotherapy and radiation therapy, which may be employed alone or in-combination in a neoadjuvant or adjuvant set-up. With recent breakthroughs in uncovering the molecular basis of different GI cancers, targeted therapy and immunotherapy have proven effective in treating GI cancer patients with specific genetic biomarkers.
Who Is It For
- GI cancer patients seeking precision medicine
- Patients with recurrent GI cancers
- GI cancer patients resistant to targeted therapy
Sample Types
Tumor tissue (FFPE block/slides, or frozen tissue)
Fine needle biopsy
Liquid biopsy (plasma and others)
INTESCAN™
Targets 52 key genes in colorectal and small intestine cancers
- Comprehensive testing of genetic alterations in APC/WNT, TP53, RAS/RAF/MAPK pathways and other related protein kinase signaling cascades
- Covers whole exons of KRAS, NRAS, HRAS and BRAF genes to better inform targeted therapy decisions
- Evaluates microsatellite instability (MSI) and mismatch repair deficiency (dMMR) to better inform immunotherapy decisions
- Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers
- Identifies potential drug resistance mechanisms
- Assesses genetic predisposition to colorectal and small intestine cancers
STOMOCAN™
Targets 60 key genes in gastric cancer
- Comprehensive testing of genetic alterations in RAS/RAF/MAPK and PI3K/AKT pathways, TP53, CDH1 and other related protein kinase signaling cascades
- Analyzes HER2 (ERBB2) gene mutations and copy number gain and PIK3CA gene mutations to better inform HER2 targeted therapy decisions
- Evaluates microsatellite instabilities (MSI) and mismatch repair deficiency (dMMR) to better inform immunotherapy decisions
- Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers
- Identifies potential drug resistance mechanisms
- Assesses genetic predisposition to gastric cancer
ESOPHACAN™
Targets 58 key genes in esophageal cancer
- Comprehensive testing of genetic alterations in RAS/RAF/MAPK and PI3K/AKT pathways, and other related protein kinase signaling cascades
- Analyzes HER2 (ERBB2) gene mutations and copy number gain to better inform HER2 targeted therapy decisions
- Evaluates microsatellite instabilities (MSI) and mismatch repair deficiency (dMMR) to better inform immunotherapy decisions
- Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers
- Identifies potential drug resistance mechanisms
- Assesses genetic predisposition to esophageal cancer
PANCRECAN™
Targets 56 key genes in pancreatic cancer
- Comprehensive testing of mutations in KRAS, EGFR, NRAS, BRAF, PIK3A and other related key genes
- In-depth analysis of deleterious alterations in BRCA1/2 genes to better inform PARP inhibitor therapy decisions
- Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers
- Identifies potential drug resistance mechanisms
- Assesses genetic predisposition to pancreatic cancer
LIVOCAN™
Targets 59 key genes in liver cancer and cholangiocarcinoma
- Comprehensive testing of genetic alterations in FGFR, MET, EGFR, KRAS, BRAF, PIK3CA and other related key genes to better inform targeted therapy decisions
- Analyzes mutations and copy number gain of VEGFR1/2/3/A genes involved in angiogenesis to better guide treatment plan
- Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers
- Identifies potential drug resistance mechanisms
- Assesses genetic predisposition to cancer
GISTCAN™
Targets 47 key genes in gastrointestinal stromal tumor (GIST)
- Comprehensive testing of KIT and PDGFRA genes to better inform targeted therapy decisions
- Analyzes mutations in BRAF, KRAS,NRAS mutations and other genes in related protein kinase signaling cascades
- Identifies potential drug resistance mechanisms
- Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers
- Assesses genetic predisposition for hereditary GIST
LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.
Learn more about our products and services or contact us today to discuss how we can partner together.